Bluenote, a US-based company focused on generative artificial intelligence (AI) solutions for the life sciences sector, has announced $10m in funding to expand its platform.
The financing round was led by Lux Capital, with participation from investors including Elad Gil, Anthropic, Menlo Ventures Anthology Fund, McKesson Ventures, Avichal Garg of Electric Capital, and Moxxie Ventures.
Other contributors include prominent figures in AI and life sciences such as Othman Laraki, Fidji Simo, Mike Nohaile, Kristen Fortney, Eric Morgen, Qasar Younis, Linus Upson, and Jeffrey Low.
Bluenote’s AI platform is designed to streamline critical workflows for life sciences organisations. It supports over 15 applications, including tasks related to regulatory filings, technical reports, risk analyses, validation documents, and Standard Operating Procedures (SOPs).
The platform aims to enable scientists, engineers, and manufacturing teams to optimise their operations by integrating AI-driven tools.
Founded by former Color Health executives Fatima Sabar and Katsuya Noguchi, Bluenote leverages over a decade of experience in developing AI solutions for healthcare and life sciences.
Bluenote’s platform employs a multi-model approach, integrating proprietary fine-tuned models with technologies from Anthropic, OpenAI, and Google. This allows the company to continuously adapt its offerings by incorporating the latest advancements in AI.
One of Bluenote’s significant features is its Retrieval-Augmented Generation (RAG) system, which processes data from various sources, including data lakes and third-party applications. The platform also incorporates traceable primary sources and placeholders for human input, ensuring outputs are accurate and verifiable.
The platform operates as a unified system that consolidates workflows, enabling life sciences companies to centralise proprietary data in a secure environment. This approach eliminates the need for multiple vendors, streamlines processes, and ensures that outputs from one workflow can seamlessly integrate into others.
Bluenote’s funding will be used to expand the platform’s capabilities, focusing on additional workflows deemed critical to life sciences operations. By reducing the time and complexity involved in tasks such as regulatory compliance and manufacturing documentation, the company aims to accelerate the delivery of new treatments and innovations to market.
